Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BECONASE AQ vs NASACORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Glucocorticoid agonist; activates glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins) and suppression of immune cell migration and activation in nasal mucosa.
Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.
Seasonal allergic rhinitis,Perennial allergic rhinitis
Allergic rhinitis (seasonal and perennial) approved by FDA
Beclomethasone dipropionate aqueous nasal spray: 1-2 sprays (42-84 mcg/spray) in each nostril twice daily. Total daily dose: 168-336 mcg.
110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.
Terminal elimination half-life of beclomethasone dipropionate (BDP) is approximately 6.5 hours after intranasal administration; active metabolite beclomethasone-17-monopropionate (17-BMP) has a half-life of about 2.7 hours; clinical context: intranasal half-life supports once- or twice-daily dosing.
Terminal elimination half-life is approximately 3-4 hours after intranasal administration; however, due to prolonged residence time in nasal mucosa, clinical effects persist beyond plasma half-life.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Major metabolite is inactive.
Primarily hepatic via CYP3A4; main metabolites are 6β-hydroxytriamcinolone acetonide and 21-carboxylic acid derivative.
Renal: <10% as unchanged drug; biliary/fecal: predominant route, with metabolites excreted in bile and feces; total elimination: >90% as metabolites via feces.
Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% of unchanged drug; biliary/fecal excretion of metabolites accounts for ~60% of total clearance.
BDP: 87% bound to plasma proteins; 17-BMP: 94-96% bound primarily to albumin.
Approximately 99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
BDP: Vd approximately 20 L/kg (high, indicating extensive tissue distribution); 17-BMP: Vd approximately 10 L/kg; clinical meaning: high Vd suggests wide distribution into tissues, mainly in lungs and nasal mucosa.
Vd is approximately 2-3 L/kg, indicating extensive tissue distribution; clinical significance: large Vd suggests sequestration in tissues, potentially prolonging retention.
Intranasal: Absolute bioavailability is <1% due to low systemic absorption; oral: negligible due to first-pass metabolism (<1%); intranasal delivery results in minimal systemic exposure.
Intranasal: Absolute bioavailability is approximately 3-5% due to extensive first-pass metabolism and limited absorption from nasal mucosa.
No dose adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
No specific recommendations; use with caution in severe hepatic impairment due to potential increased systemic exposure.
No specific dosage adjustment provided; use with caution in severe hepatic impairment, monitor for systemic effects.
Children 6-12 years: 1 spray (42 mcg) in each nostril twice daily. Children >12 years: same as adult dosing.
Ages 2-5: 55 mcg (1 spray) per nostril once daily, maximum 110 mcg (2 sprays) once daily. Ages 6-11: 110 mcg (2 sprays) per nostril once daily, maximum 220 mcg (4 sprays) once daily. Ages 12+: same as adult.
No specific dose adjustment; use lowest effective dose due to potential increased sensitivity.
No specific adjustment; use lowest effective dose due to potential increased systemic sensitivity; monitor for adverse effects.
None.
No FDA black box warning.
Nasal septal perforation,Impaired wound healing,Cushing's syndrome with excessive use,Hypothalamic-pituitary-adrenal axis suppression,Increased risk of infections,Glaucoma and cataracts,Growth suppression in children
Nasal septal perforation,Nasal irritation,Epistaxis,Candida albicans infection,Immunosuppression,Growth suppression in children,Hypothalamic-pituitary-adrenal axis suppression with prolonged use
Untreated nasal mucosal infections,Recent nasal surgery or trauma,Hypersensitivity to any component
Hypersensitivity to triamcinolone acetonide or any excipient,Untreated localized nasal infection
No significant food-drug interactions. No dietary restrictions required. Avoid alcohol if it worsens allergic symptoms.
No significant food interactions known. However, grapefruit juice may slightly increase systemic exposure; avoid excessive consumption.
Beclomethasone dipropionate (intranasal) is not associated with a significant increase in major malformations based on available data. First trimester: No evidence of teratogenic risk from epidemiological studies. Second/third trimester: No specific fetal risks reported with intranasal use; systemic absorption is minimal. However, maternal adrenal suppression may occur with high doses. Intranasal route limits systemic exposure, thus fetal risk is considered low.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnant women. Nasacort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; avoid unless clearly needed. Second and third trimesters: Limited data; use with caution. Potential fetal risks include orofacial clefts (conflicting data), intrauterine growth restriction, and adrenal suppression in neonates with prolonged maternal use of high doses.
Limited data on beclomethasone in breast milk. Systemic absorption after intranasal administration is minimal. M/P ratio not available. Likely compatible with breastfeeding; however, caution is advised with high doses. Use lowest effective dose.
It is not known whether triamcinolone acetonide is excreted in human breast milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Nasacort is administered to a nursing woman. The M/P ratio is unknown. Low doses via intranasal route are unlikely to produce significant systemic levels; however, consider risk-benefit.
No dosage adjustments are typically required for intranasal beclomethasone during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume) are unlikely to significantly affect intranasal drug delivery due to local action and low systemic bioavailability.
No specific dosing adjustments are recommended for pregnancy based on pharmacokinetic changes. Use the lowest effective dose. Increased plasma volume and altered metabolism during pregnancy may decrease systemic exposure, but intranasal application minimizes systemic absorption. No dose adjustment is typically required, but clinical monitoring for efficacy is advised.
Beconase AQ (beclomethasone dipropionate) is an intranasal corticosteroid for allergic rhinitis. Priming the pump with 6-7 actuations is required before first use or after a period of non-use >1 week. It may take up to 1 week for full therapeutic effect. Avoid spraying directly onto the nasal septum to reduce irritation. Can be used safely with oral antihistamines. Use with caution in patients with recent nasal ulcers, surgery, or trauma.
For optimal efficacy, prime the nasal spray by actuating 5 times or until a fine mist appears. If not used for 7+ days, re-prime with 2 actuations. Instruct patient to blow nose gently before use and tilt head slightly forward. Avoid spraying directly onto nasal septum to reduce risk of epistaxis. May cause growth suppression in children; monitor height regularly if long-term use. Onset of action is within 12-24 hours, but maximal effect may take 2-3 weeks.
Shake the bottle gently before each use.,Prime the pump by actuating 6-7 times into air before first use or if not used for more than 1 week.,Blow your nose gently to clear nostrils before use.,Insert nozzle into nostril, tilt head slightly forward, and spray away from the septum.,Do not exceed the recommended dose; it will not improve symptoms faster.,Rinse the nozzle with warm water after each use and replace cap tightly.,Benefits may take several days to develop; continue regular use.,Avoid getting the spray into your eyes; if contact occurs, rinse with water.,Do not use if you have an untreated nasal infection or recent nasal surgery.,Report symptoms of nasal bleeding, pain, or crusting to your doctor.
Use regularly for best results; it may take 2-3 weeks for full effect.,Blow your nose gently before each use to clear nasal passages.,Do not spray directly onto the nasal septum (the wall between nostrils).,Clean the nozzle after each use and replace the cap tightly.,If you miss a dose, skip it and continue with the next scheduled dose; do not double the dose.,Common side effects include nosebleeds, headache, and nasal irritation.,Report persistent nosebleeds, vision changes, or signs of infection (e.g., fever) to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BECONASE AQ vs NASACORT, answered by our medical review team.
BECONASE AQ is a Nasal Corticosteroid that works by Glucocorticoid agonist; activates glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins) and suppression of immune cell migration and activation in nasal mucosa.. NASACORT is a Intranasal Corticosteroid that works by Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BECONASE AQ and NASACORT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BECONASE AQ is: Beclomethasone dipropionate aqueous nasal spray: 1-2 sprays (42-84 mcg/spray) in each nostril twice daily. Total daily dose: 168-336 mcg.. The standard adult dose of NASACORT is: 110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BECONASE AQ and NASACORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BECONASE AQ is classified as Category C. Beclomethasone dipropionate (intranasal) is not associated with a significant increase in major malformations based on available data. First trimester: No evidence of teratogenic r. NASACORT is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnan. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.